Innate Pharma S.A. reported a narrower first-half net loss due to reduced expenses, with plans to focus on preclinical research and development on clinical assets. The company will streamline its organization with a 30% reduction in staffing levels, expecting completion by the first half of 2026. Chief Operating Officer Yannis Morel will also assume the role of Chief Scientific Officer. For the half year period, the net loss decreased to 21.34 million euros, while revenue and other income decreased to 4.86 million euros. Revenue from collaboration and licensing agreements declined, with shares trading 5.92% lower at 1.68 euros in the Paris market.

Read more at Nasdaq: Innate Pharma H1 Net Loss Shrinks, Plans 30% Workforce Cut, Stock Drops